Background and Objectives: Currently little data are available on the optimal treatment of drug-eluting stent (DES) restenosis. We evaluated the clinical outcomes of repeat percutaneous coronary intervention (PCI) in patients with restenosis after DES implantation in Korean Multicenter Angioplasty Team (KOMATE) registry. Subjects and Methods: Between March 2003 and January 2006, a total of 82 patients with 93 lesions [sirolimus-eluting stents (SES) restenosis; 45 lesions, paclitaxel-eluting stents (PES); 48 lesions] have undergone repeat PCI to treat post-DES restenosis. Results: Study patients with restenosis were; male 59%, diabetes 38%, and age 65 짹 9 years. The pattern of restenosis was focal in 67 (72%), and diffuse in 26 lesions (28%). DES restenosis was treated with conventional balloon angioplasty (BA), cutting balloon angioplasty (CBA), or another DES implantation, in 26 (28%), 45 (48%), and 22 lesions (24%; SES in SES restenosis [n=9], SES in PES restenosis [n=6], PES in SES restenosis [n=2], and PES in PES restenosis [n= 5]), respectively. At follow-up (mean 15.4짹8.9 months), there were no cases of myocardial infarction (MI) or cardiac death. Overall one-year major adverse cardiac events (MACE) rate, defined as death, fatal MI, or repeated target lesion revascularization (TLR), was 12.7%. Target lesion revascularization (TLR) occurred in 3 (14%) in BA, 3 (7%) in CBA, and 2 patient (11%) in another DES implantation group. However, there was no significant difference of event-free survival rates; One-year MACE rate was 20.1% in BA, 9.7% in CBA, and 12.8% in another DES implantation group (Kaplan-Meier, Log rank test, p=0.59). Conclusions: Repeat PCI in patients with DES restenosis showed acceptable and favorable mid-term clinical outcomes in our registry. Especially, CBA or another stent implantation had the tendency toward lower MACE rate than BA. A randomized large scaled study will be required to assess the proper effectiveness of various treatments of DES restenosis.